BioTelemetry (NASDAQ:BEAT) was upgraded by equities research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a note issued to investors on Monday.
BEAT has been the topic of a number of other reports. BidaskClub lowered shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. Raymond James lowered their target price on shares of BioTelemetry from $66.00 to $64.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 31st. Finally, Zacks Investment Research lowered shares of BioTelemetry from a “buy” rating to a “hold” rating in a research report on Monday. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $61.17.
Get BioTelemetry alerts:Shares of BEAT traded up $4.16 during mid-day trading on Monday, reaching $76.50. 1,208,759 shares of the company’s stock were exchanged, compared to its average volume of 540,883. The company has a current ratio of 2.68, a quick ratio of 2.50 and a debt-to-equity ratio of 0.66. The firm has a market cap of $2.49 billion, a PE ratio of 78.87, a price-to-earnings-growth ratio of 4.06 and a beta of 1.75. BioTelemetry has a 52-week low of $29.85 and a 52-week high of $77.58.
In related news, VP Heather C. Getz sold 93,383 shares of BioTelemetry stock in a transaction on Tuesday, January 29th. The shares were sold at an average price of $70.06, for a total value of $6,542,412.98. Following the transaction, the vice president now directly owns 119,085 shares in the company, valued at approximately $8,343,095.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Heather C. Getz sold 8,236 shares of BioTelemetry stock in a transaction on Thursday, January 17th. The shares were sold at an average price of $70.01, for a total transaction of $576,602.36. Following the completion of the transaction, the vice president now owns 88,797 shares in the company, valued at $6,216,677.97. The disclosure for this sale can be found here. Over the last quarter, insiders sold 177,198 shares of company stock worth $12,419,736. 8.30% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of the stock. Financial Architects Inc purchased a new stake in shares of BioTelemetry during the 4th quarter worth $30,000. We Are One Seven LLC purchased a new stake in shares of BioTelemetry during the 4th quarter worth $44,000. Parkside Financial Bank & Trust boosted its position in shares of BioTelemetry by 4,904.3% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,151 shares of the medical research company’s stock worth $69,000 after purchasing an additional 1,128 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of BioTelemetry during the 4th quarter worth $108,000. Finally, Spectrum Management Group Inc. purchased a new stake in shares of BioTelemetry during the 3rd quarter worth $115,000. Hedge funds and other institutional investors own 88.27% of the company’s stock.
About BioTelemetry
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
Featured Article: How are institutional investors different from individual investors?
To view ValuEngine’s full report, visit ValuEngine’s official website.
No comments:
Post a Comment